Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40HU3 | ISIN: US3207033099 | Ticker-Symbol:
NASDAQ
25.07.25 | 21:54
0,730 US-Dollar
-7,28 % -0,057
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALIDI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CALIDI BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CALIDI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCalidi announces reverse stock split, expected to begin trading on a 1-for-12 split adjusted basis1
FrCalidi Biotherapeutics, Inc. - 8-K, Current Report1
FrCalidi Biotherapeutics, Inc: Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 202563SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted...
► Artikel lesen
DiCalidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 242
10.07.Calidi Biotherapeutics, Inc. - 8-K, Current Report7
10.07.Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment2
09.07.Calidi Biotherapeutics secures $4.6 million through warrant exercise4
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
09.07.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds1
08.07.Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment7
03.07.Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities1
27.06.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEO205SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted...
► Artikel lesen
14.05.Calidi Biotherapeutics, Inc. - 8-K, Current Report6
14.05.Calidi Biotherapeutics GAAP EPS of -$0.18 misses by $0.032
14.05.Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report2
14.05.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights127Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered...
► Artikel lesen
02.05.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
25.04.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711158SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
► Artikel lesen
23.04.Calidi Biotherapeutics appoints new CEO2
23.04.Calidi Biotherapeutics names Poma as CEO4
23.04.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1